Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis
Hajibandeh, Shahin Hajibandeh, Shahab Raza, Syed S Bartlett, David C Dasari, Bobby V M Chatzizacharias, Nikolaos Marudanayagam, Ravi Sutcliffe, Robert P Roberts, Keith J
Hajibandeh, Shahin
Hajibandeh, Shahab
Raza, Syed S
Bartlett, David C
Dasari, Bobby V M
Chatzizacharias, Nikolaos
Marudanayagam, Ravi
Sutcliffe, Robert P
Roberts, Keith J
Affiliation
University Hospitals Birmingham NHS Foundation Trust; Manchester University NHS Foundation Trust
Other Contributors
Publication date
2025-12-08
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background: The aim of theis study was toevaluate impact of duration of neoadjuvant treatment (NAT) on surgical resection rate, resection margin, response to treatment, and survival in patients with pancreatic ductal adenocarcinoma (PDAC).
Methods: All randomised controlled trials (RCTs) of NAT in patients with PDAC were included. Effect sizes were determined for surgical resection rate, R0 resection, radiological response to NAT and 1- to 5-years survival.
Results: Twenty-three RCTs (1880 patients) were included. NAT duration≤8 weeks was associated with significantly higher surgical resection rate [66.7 % (95 % CI 57.4 %-76.1 %)] compared with NAT duration >8 weeks [33.5 % (95 % CI 22.1 %-45.0 %)]. The difference remained significant when only resectable [73.9 % (95 % CI 64.3 %-83.5 %) vs 44.7 % (95 % CI 15.9 %-60.6.%)], borderline resectable [66.4 % (95 % CI 46.6 %-86.1 %) vs 22.5 % (95 % CI 18.2 %-26.8 %)], or mixed borderline resectable/locally advanced PDAC [60.6 % (95 % CI 48.2 %-73.0 %) vs 35.0 % (95 % CI 27.6 %-42.4 %)] were considered. Moreover, when only NAT with chemotherapy considered, resection rate remained significant in favour of NAT duration≤8. No significant difference was found in R0 resection rate, partial response, stable disease, or disease progression between two groups. Intention-to-treat respected 1-, 3-, 5-years survival were comparable.
Conclusions: NAT duration >8 weeks may be associated with a reduced surgical resection rate and no apparent improvement in negative resection margin in patients with PDAC, particularly borderline resectable cases. However, it may have comparable survival to NAT duration ≤8 weeks. Future randomised evidence is needed to overcome the limitations associated with current evidence.
Citation
Hajibandeh S, Hajibandeh S, Raza SS, Bartlett DC, Dasari BVM, Chatzizacharias N, Marudanayagam R, Sutcliffe RP, Roberts KJ. Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis. HPB (Oxford). 2025 Dec 16:S1365-182X(25)01732-0. doi: 10.1016/j.hpb.2025.12.018. Epub ahead of print.
Type
Article